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Resumo 
 
 
O presente relatório descreve com detalhe o meu período de estágio curricular 
realizado durante o Mestrado em Biomedicina Farmacêutica. 
 
O estágio teve a duração de 9 meses e ocorreu na Blueclinical Lda., uma 
empresa constituída por três unidades de negócio distintas: Unidade de Fase I, 
Unidade de Investigação e Desenvolvimento e uma Unidade de Parceria com 
Centros de Ensaio - Clinical Research Partnership (CRP). 
 
A minha atividade foi desenvolvida apenas numa unidade de negócio – CRP. 
No entanto tive oportunidade de conhecer duas realidades distintas, exercendo 
funções num centro de ensaio como coordenadora de ensaios clínicos e 
funções na Blueclinical Back Office, com funções de apoio à unidade CRP, 
essencialmente na gestão de contratos financeiros e pagamentos. 
 
Neste relatório é revisto o estado de arte da investigação clínica e são 
descritas as principais atividades realizadas durante o estágio. São igualmente 
relatadas, as principais dificuldades sentidas, as estratégias utilizadas para as 
ultrapassar e objetivos que considero alcançados. 
 
A realização deste estágio foi uma excelente oportunidade que me permitiu 
consolidar os conteúdos teóricos adquiridos durante o primeiro ano do 
mestrado, obtendo a experiência necessária para ingressar no mundo de 
trabalho da Investigação Clínica. 
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Abstract 
 
The present report describes in detail my internship period, during the Master in 
Pharmaceutical Medicine.  
 
The internship lasted 9 months and was performed in Blueclinical Ltd., a 
company that has three business units: Phase I Unit, Research and 
Development Unit and Clinical Research Partnership Unit (CRP). 
 
My activities were performed in only one business unit - CRP, however I had 
the opportunity to experience two different realities, exercising functions as 
Clinical Research Coordinator at site and support functions at Blueclinical Back 
office, mainly contract management and payment tracking. 
 
This report reviews state of art of clinical research and describes main activities 
performed during internship. Along with the description of the activities 
performed, it is done a presentation of the difficulties encountered, strategies 
used to overcome them and objectives I considered achieved. 
 
This internship was a great opportunity that allowed me to consolidate 
theoretical knowledge acquired during the first year of the master, giving me 
the necessary experience to cross into Clinical Research job market. 
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1 INTRODUCTION 
 
The Master´s Degree in Pharmaceutical Medicine provides competences in the research, 
development, evaluation, approval and marketing of drugs and other health products. In the 
second year of the master, we are given the possibility of a practical component with an 
internship in a pharmaceutical company. I choose this practical component, believing it 
would be a great opportunity to consolidate the theoretical knowledge acquired in the first 
year and to promote integration into employment.  
This report describes my internship at Blueclinical - Investigação e Desenvolvimento em 
Saúde, Lda., hereinafter designated “Blueclinical”. It took place from 15th September 2014 
until 17thApril 2015, supervised by Doctor Cristina Lopes, Clinical Operations Director from 
Blueclinical and Doctor Alexandra Queirós from University of Aveiro. 
Blueclinical is composed by three business units and I developed my internship at 
Blueclinical Clinical Research Partnership (CRP). During two months I performed functions 
as Clinical Research Coordinator (CRC) at Local Health Unit Matosinhos - Unidade Local 
de Saúde de Matosinhos (ULSM), and then, I assumed functions at Blueclinical Back Office, 
performing tasks as contract manager, payment tracking, among others. 
 
1.1 CURRICULAR INTERNSHIP OBJECTIVES 
 
During my internship the main objectives established were divided in primary and 
secondary objectives.  
The primary objectives were: 
- Understand regulatory framework of clinical studies; 
- Perform study coordinator activities, understanding all activities performed in 
clinical research during the different phases of a clinical trial at site (starting in 
feasibility and ending in closeout visit) and the required specific needs associated 
with each stage; 
- Help in the start-up process of a study, reviewing financial contracts; 
- Perform strategies for payment tracking. 
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The secondary objectives were: 
- Achieve a multidisciplinary experience contacting with the different business areas 
of Blueclinical; 
- Develop interaction capabilities with multidisciplinary teams, as well as ability to 
plan and manage activities and the ability of multitasking; 
- Integrate the company's policy of quality; 
- Contribute with new ideas for development of the company showing a critical 
attitude. 
 
1.2 HOST INSTITUTION AND PARTNER HOSPITALS 
 
1.2.1 BLUECLINICAL LTD. 
 
Blueclinical is a Portuguese company created in May 2012, headquartered in city of Oporto. 
It is structured in three core business units, which provide services covering different phases 
of drug discovery process, from bench to bedside. Blueclinical´s logo is composed by three 
different tones of blue that represent the three business areas, in which Blueclinical operates. 
A brief description of these areas is provided below, giving more relevance to the unit where 
I developed my internship, Blueclinical CRP (1): 
- Blueclinical R&D - There are several public and private companies investing in 
basic research and therefore, with potential to be translated into new therapeutic 
medicines and health products, which require experienced partners. Blueclinical 
Research and Development (R&D) mission is to boost translational research in 
Portugal, supporting these companies, namely start-ups in the development of their 
projects towards commercialization. 
Blueclinical R&D provides expert advice on the creation of pharmaceutical, pre-
clinical, clinical and regulatory development plans of new drugs, preparation of 
scientific advice, and preparation of investigator brochure and investigational 
medicine dossier, business development plan, portfolio selection and funding 
application (2). 
- Blueclinical Phase I - It is the next logic step in the value chain. New R&D models 
emphasize the role of these studies in translational medicine. Blueclinical Phase I 
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mission is to conduct phase I clinical trials, in healthy volunteers or selected patient 
populations (early proof of concept). Trials are conducted in a dedicated unit with 29 
beds, located in the Hospital of Prelada, Oporto. This unit creates opportunities for 
the development of earlier phases trials, in Portugal (3). 
- Blueclinical CRP - Blueclinical CRP mission is to support clinical research activities 
at sites, promoting their growth, efficiency and gaining excellence reputation in 
clinical research. Blueclinical CRP established partnerships with several hospitals. 
  
1.2.2 BLUECLINICAL CRP 
 
The Blueclinical CRP will be more detailed in this section because it was the unit where I 
developed my internship.   
Actually Blueclinical CRP has partnerships with thirteen institutions as described in Figure1 
(4). These partnerships are achieved through a collaboration agreement between Blueclinical 
and each institution that leads to the creation of dedicated structures to support clinical 
research activities. The name given to this structure varies according to institution. 
 
 
Figure 1 - Blueclinical CRP Network. Logotypes of Institutions and Research offices created due to partnership 
with Blueclinical (4). 
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The main functions of support office performed by Blueclinical in these institutions are 
described below:  
- Organize, verify and submit the application for approval of the study to the 
Administration Board (AB) and to the Competent Ethics Committee (EC) (if 
applicable); 
- Assist clinical team in the identification of potential participants; 
- Organize visits of the participants in the study, including the logistical aspects 
associated with transport, if any; 
- Organize internal logistics associated with the study, for example the use of 
complementary exams, medical tests and pharmaceutical services; 
- Organize the logistics related to the sending of biological samples to the outside, if 
necessary; 
- Proceed to fill in administrative forms and Case Report Form (CRF) that do not have 
to necessarily be filled by members of the clinical team; 
- Organize and update the Trial Master File (TMF) of the study; 
- Function as person of contact (PC) for monitors and auditors of the sponsor; 
- Keep up to date register of activities to be invoiced to the sponsor and inform site 
about the values and invoice dates, in accordance with the financial agreements; 
- Make the preparation of audits and inspections, and organize the implementation of 
any corrective and preventive measures. 
Blueclinical CRP also supports investigators in studies of their own initiative, providing 
templates of essential documents, helping with regulatory submissions, statistics and 
publications. This support is not charged for affiliated investigators. 
The two main pillars for Blueclinical CRP are quality and training. Blueclinical CRP wants 
to implement a Quality Management System - Sistema de Qualidade em Investigação 
Clínica (SQIC) at sites. Clinical research related activities are performed under a quality 
management system that standardizes critical clinical research activities, thus assuring 
higher efficiency and compliance with good clinical practices and the legal and ethical 
requirements. A draft quality manual was presented to all institutions, and is being reviewed 
by AB. Relating to training, Blueclinical CRP stimulates and supports certification of 
investigators in clinical research offering the Clinical Investigator Certificate (CLIC) 
explained in further detail at later stages in this report (5). 
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1.2.3 UNIDADE LOCAL DE SAÚDE DE MATOSINHOS, E.P.E. 
ULSM was established in 1999 and is composed by the following units of care: 
- Primary Care Units; 
- Pedro Hispano Hospital; 
- Convalescence Unit (6). 
 
Figure 2 - Hospital Pedro Hispano (ULSM, EPE) (6). 
 
My internship took place in Hospital Pedro Hispano shown in Figure 2. For all institutions 
described in Figure 1, partnership is achieved through a collaboration protocol between the 
institution and Blueclinical.  For ULSM, this protocol was established in 18 June 2013. This 
collaboration protocol leads to the creation of a dedicated structure to support clinical 
research activities. The name given to this structure varies according to institution´s 
organogram. In ULSM, the existent structure dedicated to clinical research is Clinical Trial 
Center - Centro de Ensaios Clínicos (CEC) and with the partnership, Support Office of 
Clinical Trial Center - Gabinete de Apoio ao Centro de Ensaios Clínicos (GACEC) was 
created. 
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Figure 3 - Structure of Research Office at ULSM, E.P.E. 
CEC - Centro de Ensaios Clínicos; COD - Clinical Operations Director; CRC - Clinical Research Coordinator; GACEC 
- Gabinete de Apoio ao Centro de Ensaios Clínicos LCRM - Local Clinical Research Manager; MP - Managing Partner 
(5).  
 
In ULSM, CEC is constituted by: 
- Coordinator - Physician named by the AB that coordinates CEC. Coordinator will 
report to clinical director or his representative and to AB. 
- GACEC - supporting office constituted by workers from Blueclinical CRP: Local 
Clinical Research Manager (LCRM), and one or more CRC. All human resources 
from GACEC are qualified to operationally support activities from coordinator and 
clinical investigators. GACEC reports their activities to Clinical Operations Director 
(COD) that will report to Managing Partners (MP) of company. All CRC from 
Blueclinical sign a confidentially agreement with institution, as they will have to deal 
with sensible data like patients files. 
- Clinical Investigators that desire to become affiliate with CEC. Clinical 
investigators are health professionals who want to associate with CEC. They should 
undergo a training plan in clinical research that will be provided free of charge by 
Blueclinical - CLIC (7). 
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1.3 REPORT’S STRUCTURE 
 
This report is structured in the following chapters: 
- Introduction: Provides an overview of company and site where I performed my 
internship. It also establishes my primary and secondary objectives for my training 
period. 
- State-of-the-Art: This chapter describes regulatory environment of clinical research, 
the change of paradigm in clinical development and clinical research in Portugal. 
- Experience: Details activities performed during my internship at site and at 
Blueclinical Back Office. 
- Discussion: Identifies difficulties and challenges felt during internship, as well as 
learning outcomes and competences developed.  
- Conclusion: Integrates a summary of what internship offered me. 
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2 CLINICAL RESEARCH STATE OF ART 
 
2.1 ETHICAL AND REGULATORY CONTEXT 
 
Laws and ethical codes apply to the different stages of drug development, aiming to 
maximize public protection. Conduct of clinical research in human beings brings into 
discussion ethical issues of extreme importance, and in order to achieve the ultimate goal of 
protecting public health, clinical research is highly regulated. In European Union (EU), 
regulatory framework can be a regulation, directive, guidelines or reflection papers. 
Regulations have an immediate application for all member states, while directives have to 
be transposed into national law. Guidelines or reflection papers are not legally binding, but 
they try to provide the best or most appropriate approach to fulfill legal obligations, 
representing EU harmonized position. The use of different approaches requires justification.  
European Medicine Agency (EMA) is responsible for the scientific evaluation of medicines. 
It started its activity in 1995, is located in London and is the one responsible to protect and 
promote public health and animal health through evaluation and supervision (8). EMA 
regulates activity of 27 countries and 3 additional countries from the Economic European 
Area (Iceland, Norway and Lichtenstein).  
Figure 4, represents chronologically, the most relevant regulatory environment in clinical 
research. 
 
Figure 4 - Milestones in Clinical Research Regulatory Environment.    
ICH - International Conference on Harmonization; GCP - Good Clinical Practice. Adapted (10, 11, 18). 
 
1947
•Nuremberg Code
1964
•Helsinki Declaration
1990
•ICH creation
1996
•ICH GCP
2001
•Directive 2001/20/EC transposed into Law nº21/2014, 16th April 2014
2005
•Directive 2005/28/EC transposed into Law nº 102/2007, 2nd April 2007
2014
•Regulation EU 536/2014 , 16th April 2014
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At the end of the Second World War, after the atrocities committed with human 
experimentation, the Nuremberg Code was written in 1947, and dictates 10 basic principles 
by which clinical research in humans should be governed. The principles of the Nuremberg 
Code were extended and improved through the Declaration of Helsinki. This declaration, 
established in 1964 is considered the first international standard which describes that welfare 
of human beings is given priority over the interests of science and society, and had its origin 
in Nuremberg Code (9). It covers all important ethical considerations involved in clinical 
research, involving human subjects. According to this declaration the most important items 
are putting the well-being and safety of the subjects in front of science, the need of informed 
consent, review of ethical committee, involvement of qualified persons in the trial and 
application of scientific standards in the design of trial (9,10).  
After the thalidomide tragedy in Europe, safety and efficacy uncertainties about new drugs, 
increased the costs of research. In order to reduce costs and avoid duplication of the work, 
in 1990 regulatory authorities from EU, Japan and USA and experts of pharmaceutical 
companies joint to reach consensus about the requirements for the authorization of new 
products which resulted in the creation of International Conference on Harmonization (ICH), 
which mission is to achieve harmonization, while ensuring safe, effective and high quality 
medicines (10). This harmonization led to an economic use of animal, human and material 
resources, facilitating mutual acceptance of data by regulatory authorities in these 
jurisdictions. ICH has two essential goals: protect the rights, integrity and confidentiality of 
participants, and quality and integrity of the data collected (11). 
In 1996, was created the ICH E6 (R1) - Guideline for Good Clinical Practice (ICH - GCP), 
that is an internationally accepted standard dictated by the ICH based on the principles of 
universal Declaration of Helsinki, that sets out the principles for planning, conducting, and 
monitoring of clinical trials (12). Since the implementation of ICH - GCP, clinical trials 
evolved, and innovative approaches must be considered, for the appropriate use of 
technology. For this reason, in June 2014 was implemented ICH E6 (R2) - Addendum to 
Good Clinical Practice, that implements innovative approaches as quality risk management 
and quality by design process (13). 
Conduct of clinical trials of medicines is regulated in EU by Directive 2001/20/EC, known 
as Clinical Trial Directive. According to Directive 2001/20/CE a clinical trial is considered 
“Any investigation in human subjects intended to discover or verify clinical, 
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pharmacological and / or pharmacodynamics effects of one or more investigational 
medicinal products and / or identify any adverse reaction to one or more investigational 
medicinal product and / or analyze the absorption, distribution, metabolism  and elimination 
of one or more investigational medicinal in order to determine their safety and / or efficacy.” 
(14, p.5). Non interventional studies are excluded from the scope of this directive. 
Investigational Medicinal Product (IMP) is considered an “active ingredient in a 
pharmaceutical form or placebo being tested or used as a reference in a clinical trial, 
including products already with marketing authorization in the market but used or 
formulated differently from the authorized form, or used for an unauthorized indication, or 
intended to obtain further information about the authorized form” (14, p.6). Medicines with 
marketing authorization and placebo are also included in this definition. This directive aims 
to ensure human rights and harmonize procedures and requisites for the authorization of 
clinical trials by regulatory authorities and EC. Before this directive, European countries 
varied a lot in terms of the procedures and requirements for the conduct of clinical trials. 
This directive establishes a legal bond for the implementation of ICH - GCP, implementation 
of Good Manufacturing Practices (GMP) and establishment of a system for collecting and 
sharing information (information transparency). Clinical trial directive established two 
databases: EudraCT, an electronic database for interventional studies and Eudravigilance 
clinical trials module, a database for European report of suspected unexpected serious 
adverse reaction. It also ensures the protection of personal data (14). Directive 2001/20/CE  
was firstly transposed into Law 46/2004, 24th August, and then transposed into Law 21/2014, 
16th April, that has a broader scope of application, regulating all clinical research covering  
beyond clinical studies with medicinal products for human use, studies with medical devices, 
cosmetics and hygiene products (15). 
Directive 2005/28/CE, also referred as GCP directive lays down the principles and 
guidelines regarding IMPs for human use (16) and provides more detail on requirements of 
clinical trial directive. It was transposed into national Law 102/2007, 2nd April 2007. 
Directives and guidelines governing medicinal products in Europe can be found in volume 
10 (Eudralex) - The rules governing medicinal products in European Union, published on 
European commission website. 
Several criticisms were made to clinical trial directive, saying it led to a decrease in clinical 
trial authorization, increasing costs and human resources needed for the clinical trial 
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authorization process (17). Harmonization impact expected from this Directive 2001/20/CE 
was hindered as directive requires transposition into national law, and similar, but different 
interpretations where obtained from the different member states. On the other hand, impact 
of this legislation on the structure and activity of competent authorities led to an increased 
need of resources and a consequent application of a tax to the sponsor. 
On 16th April 2014 was published the new European regulation of clinical trials EU 536/2014 
revoking Directive 2001/20/EC. The objective of this regulation is to create a favorable 
environment for clinical research in Europe, contradicting the trend of delocalization of this 
activity to emerging countries. This new regulation proposes introduction of a new clinical 
trial authorization procedure. Main alterations are described below: 
- Harmonized authorization dossier, the submitted file is divided into part I intended to be 
assessed jointly by all Member States and part II to be assessed at national level, only; 
- Authorization requests of clinical trials connected to an EU database, free of charge to 
the sponsor; 
- Possibility of tactic authorization; 
- More flexible and rapid assessment; 
- Clearer timelines; 
- Possibility of sponsor being located in third countries provided that there is a contact 
person in the EU; 
- Differentiation of clinical trials based on risk: clinical trials of minimal intervention and 
not minimal intervention; 
- Responsibility of member states to define the organizational structure and internal 
competences for assessing clinical trial authorization application; 
- Adaptation of insurance rules; 
- Permission for co-promotion (18). 
The new regulation came into force on 6th June 2014, but nevertheless will only apply 6 
months after publication of the notice of the European Commission to the portal operation 
of the United States and EU entry database. This regulation is expected to be in practice only 
in 2016 (17). 
Clinical research is a demanding and complex activity that requires the involvement of 
various stakeholders (Figure 5): 
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Figure 5 - Main Stakeholders in Clinical Trials. Adapted (19).    
CRO - Contract Research Organization. 
 
- Sponsor - Usually is a pharmaceutical company or can be investigator, in case of 
studies from their own initiative. Sponsor is the one that takes responsibility for 
initiation, management and financing of the study. 
- CRO - Contract Research Organization is an organization contracted by the sponsor 
to perform one or more of his functions. The last responsibility is always from the 
sponsor. 
- Study team - constituted by Principal Investigator (PI) and all team needed to 
conduct the study. It may include, sub investigators, nurses, study coordinators, 
laboratory technicians, pharmacists and others. 
- Clinical trial site - is the physical place where trial activities are conducted.  
- Administration Board - studies need approval from AB of the site in order to be 
conducted. 
- Subjects - can be healthy volunteers or patients. 
- Regulatory Authorities - Sponsor has to submit an application for clinical trial 
authorization to National Competent Authority (NCA), and EC (19). If the trial is 
conducted in more than one Member State, application must be repeated for each 
Member State. First, Sponsor should acquire the unique EudraCT number from 
EudraCT database. Application details for NCA are described at volume 10 of 
Sponsor
Site
CRO
Study Team
Regylatory 
Authorities
Patients
Administration 
Board
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Eudralex and should include covering letter, EudraCT number, clinical trial 
application form, protocol, investigator brochure (or summary of product 
characteristics in case of a product with a marketing authorization) and 
investigational product dossier. NCA has 60 days to consider a valid request. NCA 
evaluates medicines, pharmaceutical quality, pre-clinical and toxicological data, pre-
existing clinical data, safety monitoring. 
Application for EC is also established in chapter I of volume 10 of Eudralex. EC 
evaluates on pertinence of trial and trial design, balance risk / benefit, suitability and 
experience of research team, quality of facilities, adequacy of written consent, 
recruitment form, indemnity and compensation in case of injury and inclusion of 
vulnerable population. EC has also 60 days to evaluate a valid request. 
In Portugal, NCA is represented by Instituto Nacional da Farmácia e do Medicamento 
(INFARMED) and EC is represented by Comissão de Ética para a Investigação Clínica 
(CEIC) (19). To conduct a trial in Portugal, submission is performed to INFARMED, CEIC, 
Comissão Nacional de Proteção de Dados (CNPD) and AB from site (20). 
 
2.2 NEW CLINICAL RESEARCH PARADIGM 
 
Pharmaceutical industry is facing a challenging period. Expenditures in R & D are rising 
resulting from a stricter regulatory environment, but this spending is not being reflected in 
an increased number of New Molecular Entities (NME) launched into the market. The loss 
of productivity is due to the increasing competition, patent cliff, the arising of generics 
market and stricter regulatory environment. Development of a NME takes in average 13 
years and costs of drug development are increasing. The need for a more efficient drug 
development plan, is actually recognized by all stakeholders (21). 
Before a drug can be launched into the market, extensive pre-clinical and toxicological 
studies are performed. Clinical trials are the most expensive part of drug development. They 
may be classified according to their objectives or according to time of study occurrence in 
clinical development. Usually clinical drug development is designated in four temporal 
phases (I to IV). This is the traditional classification, but is not always suitable as one type 
of study may occur in several phases. A fixed order in clinical development plan is not 
always needed. Nowadays a classification based on type of study is more indicated. 
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Analyzing Figure 6 we can see that types of study are usually associated with a certain phase 
of development. Nevertheless, other type of studies may occur at that development stage, 
although it is less common (22). 
 
 
Figure 6 - Correlation between Development Phases and Types of Study (22). 
 
The four development phases used in clinical drug development are: 
- Human Pharmacology studies (phase I) - Typically associated with phase I studies, 
may also be conducted in other stages. These studies usually don’t have therapeutic 
objectives and are conducted in healthy volunteers. Main objectives are to assess 
tolerance, describe PK/ PD, explore drug metabolism and drug interactions, and 
estimate activity. 
- Therapeutic Exploratory (phase II) - Usually phase II. Primary objective of these 
studies is to explore therapeutic efficacy in patients. This studies will help to 
determine the dose and regimen for phase III trials (therapeutic confirmatory). They 
provide basis for confirmatory study design, endpoints and methodologies. 
- Therapeutic Confirmatory (phase III) - Intend to demonstrate or confirm 
therapeutic benefit. They will confirm evidence accumulated on phase II, in order to 
assure drug is safe and effective for intended indication and in receiver population. 
They provide the basis for marketing approval, establishing safety profile, assessing 
risk/ benefit in order to support licensing, establishing dose response relationship, 
assessing risk/ benefit in wider populations, in different stages of disease and with 
different concomitant medication. 
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- Therapeutic Use (phase IV) - Starts after drug approval. These studies are important 
for optimizing drugs use. They intend to re access risk/ benefit relationship in general 
populations, or environments, refine dose recommendation and identify less common 
adverse reactions. These studies may also be performed for the development of an 
application unrelated with original approval use (new dosage regimens, new route of 
administration, new indication) (22). 
Classis paradigm for clinical research, described from phase I to IV, is very lengthy, costly 
and very low predictive of safety and efficacy. In this traditional model, new entities fail in 
later and expensive phases of development (21). In new model called “quick win, fast fail”, 
uncertainty is decreased before expensive later stages of development. This directs resources 
for new molecules that have higher probability to succeed. Savings gained with this new 
model can be re invested to further enhance R&D productivity (Figure 7) (21).  
 
 
Figure 7 - Traditional versus New Research Paradigm (21). 
 
This new model arises from the need of a more flexible model that takes advantage of all 
technologies, disease modeling, adaptive clinical trials, biomarkers and baysean-style 
statistical approaches. Advances in basic sciences especially the biotechnology advances in 
molecular targeting, immunology and omics sciences created a great opportunity for 
development, providing a good knowledge of diseases and its mechanisms. This new model 
is based in life testing and life licensing. There wouldn’t be only a submission for marketing 
authorization, but many submissions occurring during development, allowing limited 
launch. At the beginning, NME would be only available for a subgroup of population. As 
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more information on safety and efficacy is available, then new submissions to authorities are 
performed and extended to large populations. This new paradigm is also known as quick win 
fast fail, because it wants to bring uncertainty to the earliest phases of development directing 
resources for molecules that have a higher probability to launch. In this model, Proof of 
Concept (POC) is created with the objective of testing as soon as possible new medicines in 
humans. Here, is where a lot of molecules fail (21). 
Studies can also be classified as interventional (or experimental) or non-interventional (or 
observational). Non-interventional studies can be categorized as cross-sectional, cohort, or 
case-control, according to the objective of the research study. Main differences are described 
in Table 1 (adapted 23). 
 
 Experimental Observational 
Study Design Randomized 
Control Trial 
Cross-sectional Cohort Case-Control 
Study Population Highly selected 
population 
Diverse 
Population in a  
range of settings 
Diverse Population 
in a  range of 
settings 
Diverse Population 
in a  range of 
settings 
Directionality Exposure is 
assigned before 
outcome is 
ascertained 
Exposure and 
Outcome 
ascertained 
simultaneously 
Exposure 
ascertained before 
outcome is 
ascertained 
Outcome is 
ascertained before 
exposure is 
ascertained 
Primary Use Demonstrate 
efficacy of an 
intervention 
Screening 
Hypotheses; 
prevalence studies 
Assessing 
association 
between multiple 
exposures and 
outcomes over 
time. 
Assessing 
associations 
between exposures 
and rare outcomes 
Analysis Straight forward Sophisticated 
multivariate 
techniques may be 
required to 
account for 
confounding 
Sophisticated 
multivariate 
techniques may be 
required to 
account for 
confounding 
Sophisticated 
multivariate 
techniques may be 
required to 
account for 
confounding 
Internal Validity High Low Low Low 
External Validity Low/Moderate High High High 
Table 1- Comparison between Experimental and Observational studies. Adapted (23). 
 
As times progresses it becomes more difficult to discover new innovative drugs. 
Pharmaceutical companies need to distance themselves from blockbuster approach because 
casual discovery of “one size fits all” is difficult, lengthy and costly. If companies are not 
willing to take risks, there will not be innovation (21). Many resources are applied and 
allocated to “low hanging fruits” and efforts made in same disease areas, where return on 
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investment can be quicker. Industry of similar and generics is rising because this market has 
a cheaper and quicker development that offers much less risk. 
In order to mitigate these hurdles, authorities created benefits for medicines that fulfill unmet 
medical needs. Regulation EC 141/2000 provides incentives to stimulate innovative 
medicines such as fee reduction/ exemption, market exclusivity, scientific advice and 
protocol assistance, community marketing authorization and national incentives (24). 
Food and Drug Administration (FDA) created a draft guidance for adaptive design for 
clinical trials. Clinical trials are planned with adaptive features that can make studies more 
efficient (shorter duration, fewer patients), more likely to show effect of a drug if it exists, 
or other important information. Key value of adapting is not in reducing sample size, but 
increasing the information value, thus making adaptive designs more ethical/ efficient (25). 
In addition, other initiatives are being made to address decreased R&D productivity. Two 
examples are the FDA’s Critical Path Initiative (CPI) established in 2004 and European 
Innovative Medicines Initiative (IMI) created in 2007. IMI is a public partnership that 
involves Pharmaceutical Industry and is represented by European Federation of 
Pharmaceutical Industries and Associations and European Commission. IMI activities aim 
to develop medicines safer and faster. IMI research agenda focus on four pillars: prediction 
of safety evaluation, prediction of efficacy evaluation, knowledge management, education 
and training. IMI intends to accelerate discovery and development of new medicines in the 
area of cancer, inflammatory and infectious diseases, between others (26). CPI identifies 
opportunities that could be implemented in order to increase productivity of drug 
development. It is essentially based in the development of better evaluation tools, 
development of biomarkers and better knowledge of the disease, streamlining clinical trials, 
making use of advances in bioinformatics, moving manufacture to 21st century, and increase 
the development of medicines addressed to medical unmet needs and risk populations, like 
children (27). 
Paediatric Investigation Plan (PIP) and Paediatric Use Marketing Authorization (PUMA) are 
initiatives from EMA that play an important role in the development of medicines for 
paediatric (28). 
EMA created a Roadmap 2015 in order to accelerate evaluation and development of 
medicines for the benefit of public health. Here, objectives and priorities are established 
since 2011 to 2015. Strategic areas are addressing public health needs (stimulation of 
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medicines for unmet medical needs, medicines for rare diseases and all types of veterinary 
medicines), facilitating access to medicines (implementing activities to reduce productivity 
gap that nowadays exists in drug development) and optimizing safe and rational use of 
medicines (29). 
 
2.3 CLINICAL RESEARCH IN PORTUGAL  
 
Clinical trials are the most expensive part of drug development. Stakeholders point cost of 
clinical trials as a barrier to innovation (30). In order to save time and money, industry is 
increasingly seeking for countries that can offer the best conditions to perform clinical trials. 
In recent years, Portugal has revealed a progressive loss of competitiveness with a reduction 
in the number of clinical trials conducted, which is among the lowest rates in Europe. Large 
pharmaceutical companies are moving clinical trials out of Portugal, mainly Eastern Europe, 
Asia and Latin America which have seen an exponential growth in clinical studies. In 2014, 
5549 clinical trials were conducted in Europe, but only 127 were performed in Portugal (31). 
Clinical research is an activity that presents a very high return on investment. It is estimated 
that for 1 € invested the return will be 1.98 € which is almost the double (32). 
Clinical trials can bring a lot of benefits for our country (economic, political and social), but 
the most important ones are undoubtedly early access to innovative treatments, reduction of 
public expenditure, job creation, and increase in tax revenue positive - impact on the trade 
balance of the country (19).  
 
Figure 8-Number of clinical trials submitted to INFARMED (2006-2014). Adapted (33). 
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Figure 8 shows the number of clinical trials submitted to INFARMED between 2006 and 
2014. Between 2006 and 2013 the number of clinical trials submitted in Portugal decreased. 
The year of 2011 reached the lowest number with 88 trials. In 2014, it seems to be a slight 
increase in number of clinical trials submitted (33). Efforts are being made in Portugal to 
change this scenario.  
 
Year Phase I Phase II Phase III Phase IV Total 
2006 2 20 104 27 153 
2007 7 30 74 21 132 
2008 3 31 100 12 146 
2009 6 27 73 9 115 
2010 2 17 79 9 107 
2011 6 19 58 5 88 
2012 3 25 82 8 118 
2013 10 20 75 9 114 
2014 10 24 81 12 127 
Table 2 - Clinical Trials submitted to INFARMED per phase of Development. Adapted (33). 
 
As shown in Table 2, phase III and IV represent about 80 % of trials in Portugal. Phase I has 
almost no expression, (compared with other countries) and only 8 trials were made between 
2008 and 2012. Between 2013 and 2014 this number raised to 10 per year, which is due to 
the creation of Blueclinical Phase I. Also, therapeutic areas with more clinical trials are 
antineoplastic and immunomodulation agents, central nervous system, cardiovascular 
system and anti-infectious. Portugal as potential to grow in early stages and in different 
therapeutic areas (33). 
Compared with other countries, Portugal has a small number of sites participating in clinical 
trials as well as number of patients recruited. It is needed the approval of four entities 
(INFARMED, CEIC, CNPD and AB) which leads to an average approval time of a clinical 
trial in Portugal of about 6 months. On the other hand, we have restrictions on advertising 
of clinical trials and investigators do not have career incentives in clinical research. 
Hopefully, this scenario is changing as there is high political endorsement resulting in more 
competitive timelines from INFARMED and CEIC and the creation of structures dedicated 
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to clinical research within public health institutions. A new law for clinical research was 
approved in 2014, but there is still room for improvement.  
A study performed by Associação Portuguesa da Indústria Farmacêutica in 2013 suggests 
initiatives that could narrow the gap between Portugal and Europe. Portugal can follow the 
examples of other countries to understand what could potentiate increase of clinical trials. 
Some of the measures proposed are revision of legislation for the approval process and 
revision of legislation for advertising clinical trials (actually advertising is very restrictive 
falling into medicinal products advertising), as dissemination and publicity could increase 
Portugal´s ability to recruit. Other proposed measures are revision of the clinical research 
component in the career development of researchers, creation of structures dedicated to 
clinical research and review of legislation to promote research of academic nature (19).  
A favorable legislative environment coupled with interested researchers and institutions is 
extremely important but above all Portugal needs sponsors willing to develop clinical trials 
here. Unfortunately most of the times, Portugal is not considered an option and lack of 
information still exists about the potential that Portugal may have in clinical research (19).  
In 2013 the company Blueclinical CRP established partnerships with various public hospitals 
in a strong attempt to promote clinical research. 
For the success of clinical research in Portugal we have to look to the interests of all involved 
stakeholders: patient, investigators, institutions, society and sponsors. 
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3 EXPERIENCE 
 
My training experience was mainly divided between two major functions: 
- CRC (two months);  
- Blueclinical Back Office, mainly as contract manager (seven months). 
This chapter intends to describe activities performed during the time dedicated for each 
function. One more section is added to this chapter in order to describe other tasks 
performed during my internship.  
 
3.1 EXPERIENCE AS CLINICAL RESEARCH COORDINATOR 
 
During my internship I performed functions as CRC at ULSM. This experience was short, 
but provided me an overview of the different and interrelated activities performed at site 
during a clinical trial. 
 
3.1.1 FEASIBILITY 
 
Site is the physical place where clinical studies can be conducted. Sponsors are increasingly 
focusing in the correct choice of the site. Feasibility questionnaire intends to assess site´s 
conditions. Feasibility is an important step as the choice of the site can help to manage costs 
and may be critical for the success of the study. Site should produce reliable, reproducible 
data and produce it in a timely and safe manner. Sponsor is looking for short approval 
process, experienced and motivated teams, necessary facilities and equipment, time to 
conduct the study and patient enrollment capability. For this reason, feasibilities 
questionnaires are usually similar and focused in questions about submission process and 
timelines, facilities and equipment, number of patients with target disease seen by site in one 
month, recruitment experiences from past, recruitment strategies, competitive trials and 
experience of study team (34). Feasibilities could be on paper or online but usually both of 
them are extensive and not very appealing to fill. Sponsor´s first contact is usually by phone 
or by feasibility survey e-mail. Sponsor provides few information about the study like the 
name of active substance, title of protocol and disease and tries to assess the potential interest 
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of institution/ PI in that trial. Then, sends a confidential disclosure agreement to be fulfilled 
by PI that states that PI will not disclose any confidential information contained in protocol 
synopsis or questionnaire sent.  
As a CRC, feasibilities were a difficult step as I felt some resistance in the filling of these 
extensive and time consuming questionnaires. Physicians are always much occupied and 
sometimes could not understand the importance of answering this questionnaire that most of 
the times had narrow deadlines. This issue was mainly overcome, trying to help physicians 
answering feasibilities. Usually I printed questionnaire and tried to evaluate which questions 
I could answer, to optimize this process (such as facilities questions or about submission 
process) and minimize time spent by physicians answering these questionnaires. 
Blueclinical has a person responsible for feasibility management. Feasibities could come 
directly to institution or from Blueclinical Back Office. My colleague always tried to expand 
questionnaire from our site to our CRP network, to maximize the possibility of site selection 
within our CRP network. 
Feasibilities are an extremely important step as they will dictate the possibility of site 
selection. 
 
3.1.2 SITE QUALIFICATION VISITS 
 
Assessment of site conditions may include face-to-face visits. These are called site 
qualification visits. Sometimes this step is suppressed in order to minimize costs. Sponsor 
staff visits the site and most of them have checklists of requirements that site should have 
for selection. During my internship I had opportunity to attend one selection visit from one 
sponsor. In this visit, me and my colleagues scheduled an appointment with key site staff 
and departments in order that sponsor could check available resources, maintenance and 
calibration of equipment, workload of the site and staff competence. Study team Curriculum 
Vitae (CV) and GCP training are usually requested. 
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3.1.3 INVESTIGATOR MEETINGS 
 
After site selection, investigators meetings are performed. Competence of PI and site team 
is site´s responsibility but it is sponsor´s responsibility to provide training in protocol related 
procedures. All staff working in the trial should have GCP course, but meetings are an 
opportunity to meet other investigators and to obtain expert advice on trial procedures and 
study design. Investigator meetings are usually attended by PI and key elements of staff 
team. Review of protocol and trial procedures, data entry procedures, problems that may 
arise and how to prevent them, CGP, safety aspects, IMP accountability and administration, 
are some of the focusing items. 
 
3.1.4 SUBMISSION PROCESS 
 
During submission process, me and my colleagues provided sponsor, Blueclinical´s 
“Submission Package”, which has a set of documents needed for submission. Sponsor 
usually requested three main documents: PI CV, protocol page signature by PI and 
declaration of site conditions. Blueclinical created a template for CV, specific for clinical 
research focusing in clinical trial experience and GCP training. Declaration of site conditions 
adapted from Blueclinical involves all head of departments that sign this declaration stating 
resources, facilities and equipment available for the trial. Other two important documents 
are requested by CEIC due to position of CRC in the site: declaration signed by Blueclinical 
authorizing CRC participation in that trial and a declaration from AB, also authorizing CRC 
participation. This last document is usually signed by our coordinator from the site. Financial 
agreements are also an important step in submission process, but I will detail it later in this 
report. 
 
3.1.5 TRIAL RELATED PROCEDURES DURING VISIT 
 
3.1.5.1 Study Visits 
 
Study visits were the most challenging activity performed at site. This was a task that 
required previous work and organization, in order to get all necessary information, avoiding 
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protocol deviations. Experience gained over the visits was crucial for my self-confidence in 
activities performed. 
Study visits were prepared in order to be compliant with all the procedures requested by 
protocol. CRC has an important role in the conduct of study visits. Some tasks were 
performed in order to achieve complete and correct collection data during visits: 
- At least one week before, we checked availability of all necessary materials needed 
to conduct the visit (e.g. collection kits, necessary material for sending samples, 
patient questionnaires, if applicable).  
- Remembered PI of study visit and the important issues from that visit. In clinical 
research “what is not written did not happened” and for that reason all must be 
documented in patient file. Physicians are not used to write everything about the 
patient in clinical practice routine, and in order to help the doctors with this tasks we 
made checklists with information that should be written in patient file.  
- In the day before we contacted study participant alerting about study visit and 
reminding to bring the study medication, the patient diary, required fasting or other 
applicable conditions. 
- Previous identification of information and data to be collected during the period 
patient is at site. We carefully read the protocol section that explains procedures 
performed in each visit. Besides that, prior knowledge of the information required in 
the CRF for that visit minimizes faults of information filled in the source document 
completed on the day of visit such as patient file. 
 
3.1.5.2 Documents 
 
During internship, at site, I had to use several documents. Below I will describe the most 
important ones. 
Protocol is the cornerstone for the conduction of clinical studies. It describes rationale, 
objectives, design, methods, statistical methods and organization of the trial. Before any 
study visit, protocol was reviewed in order that visits were compliant with all procedures 
requested by protocol. 
 
27 
 
During the trial a large number of documents is generated. Some documents are in TMF 
before the trial begins, while others are added during and after the trial. During Internship I 
was also responsible for maintaining TMF updated. It is very important to control versions 
of documents to understand what version is currently in use. 
Informed consent consists of two documents: information sheet and consent form.  Informed 
consent must be signed before any trial related procedure is conducted. It contains 
information about the purpose of the trial, entry criteria, trials procedures and possible risks. 
It must be written in Portuguese and in a language understood by the average subjects. 
Patient should be given time to read information sheet and to discuss all doubts with PI, trial 
staff, and/or discuss it with family before entering in the trial. Two copies are provided to 
patient and he should sign both if he accepts to participate in the trial. PI also signs. One 
copy is returned to the patient and the other is archived in TMF. This was an item many 
times checked during monitoring visits. 
Source documents are all documents that contain source data. Examples are medical records, 
laboratory reports, subject’s diaries, pharmacy dispensing records, and radiographs. These 
documents are important during monitoring visits allowing monitor to confirm data collected 
in CRF. 
 
3.1.5.3 IXRS  
 
IXRS (Interactive Voice/ Web Response System) is an useful system, improving inventory 
management and facilitating blinding procedures. For every study visits I had to contact with 
IXRS. IXRS can be IVRS (Interactive Voice Response System) or IWRS (Interactive Web 
Response System). To use IXRS I must dial phone number or enter web platform. In ULSM 
I used both systems. After entering the system I had to confirm patient number, date of birth 
and visit performed. Subsequently medications codes were provided and a confirmation e-
mail was sent to study team. 
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3.1.5.4 Biological sample Processing 
 
Most visits require urine and/or blood samples collection. Central laboratories are 
increasingly used as they can ensure standard methods and reduce variations among sites. 
Besides that, they send results to main database reducing transcription errors. However, in 
some trials the speed of local results is essential. Usually, when a central laboratory is used, 
an adequate package for samples and delivery of samples is provided. International Air 
Transport Association for transportation rules for biologic samples need to be followed and 
site staff responsible for packaging samples requires appropriate certified training. Although 
I did not need to process and pack biological samples, me and my colleagues completed 
appropriate e-learning training. 
 
3.1.5.5 CRF completion 
 
CRF may be electronic or in paper. I only had opportunity to use electronic CRFs. Electronic 
data entry is the process of entering data directly into a computer database, and has 
advantages over the paper, like reminders for missing responses, and for inconsistencies 
found or invalid data. Each user (PI, study coordinator or other appropriate element of study 
team) has a username and a password associated, so that all data entry and changes 
performed can be easily traced. Usually I completed CRF in the same day or on the day after 
the visit. In cases where some information was missing I asked the PI to make patients files 
amendments in the same day or day after so everything in the CRF could be checked against 
source documents.  
 
3.1.6 MONITORING 
 
It is sponsor´s responsibility that trials are monitored. A monitor acts as a quality control 
supervisor that usually monitors the same trial at different sites. Monitor is the link between 
the site and the sponsor. He makes regular visits to the site that should be scheduled, so that 
staff team can dedicate some time to answer monitor´s questions and to correct possible 
mistakes in CRF. 
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During monitoring visits, monitor usually checks: accuracy and completeness of data entry, 
eligibility of the patient, concomitant illness and medication properly documented, informed 
consent properly signed and dated before any study related procedure.  
During my internship I assisted to some monitoring visits. I usually requested patient files 
for monitor verification and assured the CRF was complete. During monitoring visits 
monitor helped to solve some pending queries in CRF. 
 
3.2 EXPERIENCE AT BLUECLINICAL BACK OFFICE 
 
During my experience at Blueclinical Back Office main activities performed were database 
organization, contract negotiation and payment management. Each task will be described in 
more detail in the next sections. One more section is included for others tasks performed 
during my internship. 
Changing from site, as CRC, to Back Office was a great challenge that Blueclinical proposed 
me. Company´s growth started to request that some specific tasks were centralized and, 
allocated for a specific person. Physical location of the sites and dispersed information was 
a barrier for Blueclinical development. 
 
3.2.1 DATABASE ORGANIZATION 
 
First task performed assuming new functions was database organization. All studies from all 
sites were organized by sponsor and protocol. For each protocol an obsolete paste was 
created for all obsolete versions of protocol or financial agreements. Protocols were 
organized by version and date of approval and contracts ordered by Clinical Trial Agreement 
(CTA) or Financial Agreement (FA). In case of draft versions, indicating the draft number 
and reviewed by whom (B- Blueclinical, S- Sponsor) and in case of final contract indicating 
the word final and signature date. 
Besides database organization, I also had to group information of all study visits performed 
in the different sites and about the recruitment status of patients for all studies. This 
information was obtained from each study coordinator at site. 
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Main difficulties felt during this task was some missing information as study protocols, or 
signed financial agreements, which were overcome requesting monitors of the studies the 
missing documents. 
 
3.2.2 CLINICAL TRIAL AGREEMENT NEGOTIATION 
 
According to article 13 of Law 21/2014, 16th April 2014, the sponsor or his authorized 
representative shall carry out a financial agreement with the site for the conduct of research 
activities. 
Clinical trial business is very competitive. Despite the strong competition it is important that 
site evaluates CTA and budget given, before accepting all studies proposed. In many cases, 
CTA are an overlooked step, considered as time consuming, boring and unnecessary. The 
budget of a financial agreement can only be considered valid and accepted, if not harmful to 
the hospital, thus it is very important to review CTA. 
CTA negotiation began to be made centrally by me with the support of Doctor Cristina 
Lopes, and started to be my main task during internship. This is an activity that used to be 
made individually by each study coordinator at site. CTA negotiation centralization 
improved efficiency of the company, becoming more consistent and focused in contract 
revision. Having a person allocated to this task resulted in: 
- More consistent approach of CTA negotiation; 
- Prevention of work duplication (the same contract is reviewed only once, even if 
submitted in more sites, only being necessary adaption to the particularities of each 
site); 
- Easier contact with the sponsor (sponsor knows that company has a PC allocated for 
contract negotiation). 
After site qualification sponsor contacts site and/or Blueclinical Back Office to obtain 
information required for contract completion: 
- How contract revision is performed; 
- If site has a specific contract for financial protocol; 
- Site general budget split; 
- Research team allocated to the study; 
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- Complementary Means of Diagnostic and Therapeutic (CMDT) made locally at site  
or at central laboratory; 
- Site submission process ( e.g. parallel submission is allowed); 
- The procedures for reimbursement of patient expenses. 
Usually, during contract negotiation, sponsor presents two documents: 
- CTA - More dedicated to include general and legal clauses. 
- FA - More dedicated to financial aspects. Either sponsor´s specific draft or site´s 
template may be used. Blueclinical has partnership with two sites that have their own 
financial protocol template. In most cases, financial protocol is incorporated as an 
annex in CTA. 
For CTA review and negotiation it is important to consider applicable legislation described 
below: 
- Law 21/2014, 16th April 2014 - Clinical research investigation Law (15); 
- Ordinance nº20/2014, 29th January 2014 - Table of prices charged by National Health 
System (35); 
- Ordinance 306 A/2011 de 20th December 2011 - Value of moderating fees (36); 
- Announcement nº1/2015 - Updates moderating fees values (37); 
- Decree Law nº113/2011 de 29th November, 2011- Moderating fees-special regimens 
of exemption or reimbursement (38).  
- Decree Law nº128/2012 de 21th June 2012 -First change to Decree Law nº113/2011 
(39).  
One of the most important steps during this task is clinical trial budget evaluation. It is crucial 
to consider all the work associated with the study, which is not limited to study visits or tests 
and materials spent. 
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Costs pre-study - Protocol review 
- Site initiation 
- Site qualification 
- Site pre-screening activities 
- Training of study staff 
- Pre-study visit 
- Qualification visit 
- Attendance to investigator meetings 
- Organization of initiation meeting 
- Submission work 
Costs during study - Screening 
- Subjects enrollment 
- Subject visits and procedures 
- CRF completion 
- Query resolution 
- Study inspections, audits and 
monitoring 
Costs post-study - Study close-out 
- Archiving 
Table 3 - Examples of activities that can generate costs in a clinical trial. Adapted (40). 
 
It is critical to consider time spent in pre-study, during study and post study as budget is 
expected to cover all expenses arising from the study. In Table 3 are described some 
examples of activities that can generate costs during a trial and that should be taken into 
consideration (40). 
Contract negotiation performed within Blueclinical CRP requires input of various 
stakeholders: 
- Sponsor/ CRO; 
- Blueclinical Back Office; 
- PI;  
- CRC; 
- PC. 
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Figure 9 - Blueclinical Flowchart for Contract Negotiation. 
CRC-Clinical Research Coordinator; CRO - Contract Research Organization; PC- Person of Contact; PI - Principal 
Investigator. 
 
 
Figure 9 describes sequential steps during contract negotiation. After site qualification, I 
usually requested sponsor/ CRO, documents for CTA review, which may include: 
- Protocol; 
- Detailed Budget; 
- CRF blank ( it is important to check CRF as it can be very lengthy and complicated, 
or have a lot of scales); 
- Laboratory manual ( may be requested to understand the circuit and specific needs 
to deal with samples). 
Schedule of assessments is a great summary of study requirements. It is important to assess 
number and complexity of scheduled visits and all itens described in protocol that will 
generate costs. Based on scheduled of assessments I created an excel spreadsheet template 
to estimate costs associated. CRC allocated at site, gave me, through PI, information about 
budget split. Contract is reviewed and sent to Sponsor until a final version is reached. Some 
sites require site revision and in those cases, after a final version is achieved with the sponsor, 
I send CTA for site PC. After reaching a final version, contract can be signed by sponsor, an 
then by site and PI and/or Blueclinical. 
During contract negotiation I had to daily  fullfill  a document called “Contract Registration”.  
Here I had to register: 
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- Dates of reception and sending of contracts; 
- Causes for delay ( L-Legal, F- Financial, G- General); 
- Responsible for delays ( S-site, B- Blueclinical, S- Sponsor). 
 
Blueclinical has a checklist to help reviewing CTA. This checklist is mainly divided in 
general clauses, recruitment, supply, payments and other important clauses. 
 
3.2.2.1 General Clauses 
 
General clauses are related to items that must be in the contract, for example, the 
identification of the involved parts, scope of contract, identification of PI, terms and 
termination of contract, effective date and responsabilities from involved parts. I always 
checked the presence of these itens  in the contract. If not present I requested to add this 
information. 
Depending on the site two options are available in terms of CTA: tripartite (sponsor, site, 
PI) or quadripartite (sponsor, site, PI and Blueclinical).  
 
3.2.2.2 Recruitment 
 
The itens on the checklist related to the recruiment are the number of participants to be 
enrolled in the study and end date of recruitment. The information related to the recruiment 
is relevant for site as amount of effort required to initiate a new protocol varies little with 
the number of patients that should be enrolled. Effort and time of initiating a trial should be 
considered and evaluated versus the profit margin per patient. It is important to distinguish 
between fixed costs or up front costs and variable costs. The first ones,  are costs needed for 
study conduct and are incurred whether or  not, a subject is enrolled. Sometimes sponsor 
requested not to put  in CTA the end date of recruitment to avoid the need of an amendment 
to contract, in case timeline is modified. Expected number of enrolled participants is 
important as it helps Blueclinical to plan invoicement. 
 
 
 
 
35 
 
3.2.2.3  Study Materials 
 
CTA should contain information about study materials, including supply, compassionate 
use, destruction and equipment. 
Sponsor should freely supply the site with study drug, comparator, placebo and materials 
needed to perform the study (patient diary, filters, saline solutions, rescue medication), CRFs 
or access to data capture system. Reviewing protocol helped me to identify all  materials 
needed, in order to request sponsor for supply or reimbursement of these items. After 
completion of trial, I  tried to negotiate with sponsor that, if applicable, marketed unused 
study materials that were in perfect conditions, were donated to site for use in standard 
practice. 
According to national legislation after the end of the trial sponsor should provide study 
participants with study drug for as long as conditions described below are meet: study drug 
is still not marketed, has proven to be safe and efficacious for the study participant, PI 
considers that study drug supply is clinically important to the study participant and there are 
no comparable therapeutic alternatives in terms of safety and efficacy to the study drug. This 
is called compassive use. When applicable, I requested this information to be included in the 
contract. 
After conclusion of the study or termination of the agreement, used and unused study 
materials, could either be returned to the sponsor or destroyed at site. Upon sponsor request 
site may dispose study materials. There are specific cases that require site disposal, like 
hazardous material, that should  be destroyed at site, according to site normal procedures for 
hazardous material handling. e.g., cisplatin. In case destruction is performed in the site , I 
usually requested sponsor to pay a fee for the costs incurred with study material disposal. 
Site should keep appropriate records to document destruction, and destruction should 
comply with applicable legislation.  
Site is responsible for having all equipment available at site ready. In specific cases sponsor 
may agree to provide site some equipment. Ideally, equipment provided by the sponsor 
should be described in financial agreement. Unless otherwise agreed in writing equipment 
should be returned to the sponsor at the end of the trial and site is responsible for using 
equipment according to instructions, and for its appropriate maintenance and calibration. 
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3.2.2.4 Payments 
 
In contract revision it is helpful to separate between costs site will incur with staff (direct 
costs) and costs with equipment and materials (indirect costs). National legislation specifies 
that direct and indirect costs should be clearly stated in CTA and/ or FA.  
Direct costs are costs intended to compensate study staff for their work during the trial. It 
includes study visits related work and study related fees. Study staff includes PI, sub 
investigator, nurses and study coordinators, among others. In assessment of direct costs it is 
important to estimate time needed for scheduled visits, staffing needs for study duration, 
recruitment effort needed, time spent in conference calls, e-mails, CRF completation, 
reporting SAEs, monitoring visits and shipping samples. Payment of study staff has to take 
into account not only value/ hour, but also, vacations, increased salaries (depending on 
duration of study). CTA and/or FA should identify in an individual basis and function 
performed, the remuneration of the researcher and the other team members. Direct costs may 
also include the following fees: 
- Start up fee - fee to compensate for administrative work needed to start the study. 
This payment  intends to pay, but is not limited to, protocol-related training 
requirements, submission for approval by AB and getting all site documents needed 
for study submission to regulatory authorities. This amount should be paid after the 
signature of the agreement. This fee may be given or negotiated by the site. I always 
try that  these fees are non-refundable and apart from patient enrollment fee.  
- Coordinating Investigator fee - this fee intends to pay for work of investigators in 
case national coordinator is from that site. 
- Close-out fee - this fee intends to pay for administrative work with site close-out 
activities and archive maintenance. 
 
Indirect costs include consultations, CMTD, patient fees, patient expenses and unscheduled 
hospitalization. CTA and/ or FA should clearly state all the procedures performed during the 
trial.  Consultations and CMTD related costs should be detailed  indicating National Health 
System (NHS) code, price of item performed, patient fee, number of times the item is 
performed and total value. Listing all the procedures performed during the study shows the 
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indirect costs site will incur with consulations, and laboratory testing. Price established in 
CTA and/or FA, cannot be lower than price established in NHS table.  
Sometimes, protocol requires exams, which by their specificity, may not be available in all 
sites or the site cannot guarantee they are performed according to protocol schedule of 
exams. This information should be clearly stated in CTA and/ or FA and a description should 
be made of what will be performed at site and what will not. 
The expected gain for a study participant is in health gain and not material. However, 
participation in clinical trials may result in costs and economic losses to its participants, so 
it is fair to reimburse any losses suffered by the participants arising from their participation 
in clinical trials as lost wages, travel expenses and food. It is not a benefit or incentive to 
participate in the clinical trial, but a way to offset the costs of participants. Therefore, sponsor 
should support costs due to reimbursement or compensation for expenses and damages 
incurred by study participants and where applicable, by their legal representative. Study 
participants have to submit the appropriate documentation (e.g., invoice, statement of the 
employer, proof of social security on how he/she is not receiving any sickness or 
unemployment benefits) in order to be reimbursed. Expenses are reimbursed by sponsor on 
a pass-through basis, upon receipt of an original itemized invoice, and site is responsible for  
delivering to study participant the amounts due to expenses reimbursement (41).  
Study participants may need to perform for safety reasons due to their participation in the 
study, unscheduled visits or more procedures than originally planned by the protocol when 
such activities become essential due to a change in the patient’s clinical status (e.g. on the 
occurrence of an adverse event or serious adverse event). In case adverse event is considered 
probably related with study drug, sponsor/ CRO should be responsible for this payment, and 
this information should be part of CTA and/or FA.  
According to national law, remuneration of PI and research team is allowed. In case PI and 
research team are NHS workers, payments are made through institution (15). This is 
applicable for all institutions with whom Blueclinical works for. In the case of tripartite 
agreements there is only one payee (institution), while in the case of quadripartite agreement 
there will be 2 payees (institution and Blueclinical receiving their share directly from 
sponsor). General budget distribution must also be included in CTA and/or FA. This varies 
among the institutions, that choose the best way to make their budget distribution. Apart 
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from that, distribution should be individualized between research team. Advanced payments 
(like start up fees) should be stated as well as payment schedule and payment method. 
Usually, sites complain they wait a long time to receive money from research companies. I 
always requested for a quarterly payment so the site and research team can be motivated. 
Usually payments performed are made by bank transfer, so it is important to state the bank 
details in the CTA and/or FA. Usually I request sponsor to use a simple denomination for 
bank transference: name of the responsability center - protocol code - payment period and 
parcel. This will help to identify what visits are being paid. 
 
3.2.2.5 Other Important clauses 
 
Other important clauses that should be present in a CTA are: monitoring, audits, inspections, 
safety information, archive, civil responsibility (according to article 15º from national law, 
sponsor has to get an insurance intended to cover civil responsibility), confidentiality, 
intellectual property, publications and force majeure. 
 
During contract negotiation I was able to identify several challenging itens, namely:  
- Start up fees; 
- Procedures called standard of care; 
- Reimbursement of salary losses; 
- Unscheduled visits and unscheduled hospitalizations; 
- Compassionate use of study drug. 
These were mainly solved by the following activities: 
- PI interview and staff team  to determine procedures standard of care; 
- Invoicing unscheduled events as passthrough costs (e.g hospitalization). 
 
3.2.3 PAYMENT MANAGEMENT 
 
Sites usually complain about slow payments and reimbursements. It is extremely important 
to manage receivables in order to collect all it is owned to site. 
It is important to keep track of payments: know what needs to be invoiced, and when, as per 
contract. This was my main responsibility. First task performed was asking my colleagues 
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all information they had about payments. I had to group information on payments performed 
to the site, site´s invoice number and date of payment. Some sites had this information more 
or less organized, while others did not. Then, I contacted sponsor, in order to get the most 
accurate information on payments already performed to site. I did this for all sites and for all 
studies. Actively seeking information from the sponsors created some constrains, but easily 
overcome.  
CRC at site, had to complete a map of weekly activities and I was responsible for gathering 
this information in a database. This database allowed me to maintain control over payments 
due to sites. 
When I am reconciling payments, payment detail is requested when not provided and all 
discrepances are clarified with the sponsor. 
 
3.3 OTHER ACTIVITIES 
 
3.3.1 QUESTIONNAIRES OF INTERESTS 
 
Questionnaires of Interests are a strategic tool for the development of Blueclinical CRP. It 
is an electronic questionnaire that has two main objectives: 
- Understand who are the physicians interested in performing clinical research in 
Portugal; 
- Understand their areas of interest. 
This questionnaire has a list of all possible clinical pathologies that physicians will have to 
choose. This will help to characterize which are the main interests of our physicians in 
Portugal and Blueclinical can proactively search for new projects to Blueclinical CRP 
network. Physicians were requested to respond via an electronic questionnaire. While at 
ULSM, I had opportunity to collaborate in collecting this information. 
 
3.3.2 QUALITY SYSTEM 
 
A Quality Management System (QMS) is a formalized system that documents structure and 
responsibilities to achieve quality management (managing a process to achieve maximum 
customer satisfaction at the lowest cost while continuing to improve process). QMS makes 
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an organization more process oriented, customer focuses and with the ability to do 
everything better, thus giving an organization, competitive advantage.  
Quality manual is an official document where companies detail how QMS operates. The 
format and structure of the manual will depend on company´s size and complexity. A quality 
manual usually has: company organization, company mission, vision, values, company code 
of conduct and quality policy. 
A Standard Operating Procedure (SOP) is a set of guidelines used consistently to dictate a 
set of actions performed in a given situation. An effective SOP template allows to build 
uniform work instructions that are linked to some type of design, development or assessment 
tools. These instructions promote consistency, structure and control in the workplace and 
they meet regulatory requirements of the relevant governing body. SOPs have to give 
specific information such as who will perform the task, what materials are necessary, where 
the task will take place, when the task shall be performed and how the person will execute 
the task. To achieve consistency and structure, processes must be put in place to ensure that 
SOPs are in writing, consistently formatted, reviewed regularly, approved by management, 
version controlled, indexed, used regularly, archived and document controlled.  
QMS can bring competitive advantage to a company. All employees of a company make 
part of the QMS that is everyone´s responsibility.  
During my internship I produced two SOPs: Contract Negotiation and Invoicing Control. 
 
3.3.3 TRAINING 
 
During my training I had opportunity to perform e-learning and face-to-face training. All the 
training performed was recorded in a training log sheet that has a template created by 
Blueclinical. 
Contract negotiation, pharmacovigilance, and project management are examples of some 
issues where I had face-to-face training. I also performed some self-study sessions e-learning 
(GCP, adverse events reporting, informed consent) and some webinar sessions mainly 
related with clinical trial budget and clinical trial agreements. 
During internship I had opportunity to complete CLIC level 1. CLIC arose from the need to 
improve clinical research training in Europe, in order to make Europe more competitive, 
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with qualified healthcare professionals. It is extremely important that healthcare 
professionals have access to a specific training adapted to the current requirements of clinical 
research. CLIC is a free training available in e-learning format. It is a flexible course, suitable 
for healthcare professional needs. CLIC is created through the cooperation of two entities: 
Pharma train (training for the development of new medicines, in which clinical trials are 
critical) and Ecrin (infrastructure dedicated to academic research and studies from 
researcher’s initiative). The first version was implemented in March 2013 and the Portuguese 
version was available in June 2014. 
CLIC has three different levels: level 1, dedicated to sub-investigators and non-medical staff 
(16 hours), level 2 dedicated to PI (additional 24 hours) and level 3 in case PI is 
simultaneously sponsor (additional 24 hours).
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4 DISCUSSION 
 
My internship was linked to a Hospital (site) and to Blueclinical Back Office, which gave 
me the opportunity to see two different realities that complement themselves. During this 
period I had opportunity to perform diversified tasks. This learning model that integrates an 
internship in the second year of the master, proved to be efficacious, as it helped me to 
consolidate all I learned in the first year of the master.  
I am a pharmacist and I have worked 9 years in a pharmacy, but environment is completely 
different so I believe I felt the same difficulties that my younger colleagues felt during 
internship. This was challenging as it was a new area for me where I did not felt comfortable. 
This curricular training contributed to my experience and for the development of my hard 
and soft skills. Professional market is increasingly seeking professionals with social 
competence and communication (soft skills). In clinical research, soft skills are extremely 
important as they improve the relationship and communication with all involved 
stakeholders: study team, colleagues, pharmaceutical industry (clients) or our supervisors. 
During this period I have learned how to deal with the unexpected and to solve problems, 
always looking for the better solution. Experience at site, although being short, was very 
rewarding. It was my first experience in clinical research world and gave me opportunity to 
understand the different steps that a trial goes through, within a site. CRC works with 
research study team under the direction of PI. PI is the ultimate responsible for the conduct 
and management of the study but CRC supports, facilitates and coordinates daily activities 
playing an important role at the site. 
Main constrains experienced as CRC were to get responses of physicians for feasibilities, or 
the constant lack of availability of physicians to spend time with CRC for signatures, or 
papers needed for submission. I think that difficulties felt at the beginning improved over 
the time as physicians have gained confidence in CRC team. Strategies used to overcome 
this problems were helping the physician to fulfill feasibilities as there are some specific 
questions about facilities that CRC could answer. 
Study visits were always difficult to perform as I was not used to it. With experience I 
understood that a good preparation was the key for success of study visits. A good knowledge 
of procedures requested by protocol and CRF was crucial. If I was well prepared I felt much 
more confident that anything would miss. 
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In clinical research, study procedures must be strictly followed. I have learned that “what is 
not written does not exist”, so, it is important to be rigorous in the tasks performed. It also 
helped me to think in monitor point of view, what they would like to check. Information in 
CRF, had to be in a source document. For example if physical exam of patient was normal, 
I could not assume it was normal just because PI did not wrote anything in patient file. In 
this case it had to be written “Physical examination- normal”. 
Reading and understanding a study protocol was challenging and a difficult task, mainly 
because of unawareness of its organization and the use of specific terms. This was a task that 
I think I improved a lot with practice as I overcome language barrier of some specific terms 
and I get used to protocol organization, learning where to look for further information. Some 
protocols, are extremely complex, like in oncology, but with practice, I have learned to 
understand it. Good English knowledge is crucial in this area that I think that I have 
improved.  
Other big difficult felt was time management. We always deal with deadlines to perform our 
tasks and I was not used to it. This was also improved, since as we do different tasks, we 
gain experience, making it better and quicker, thus being more efficient. 
Blueclinical encourages me and my colleagues to be autonomous which can be scary at the 
beginning, but contributes a lot for our growth. We cannot learn if we just see the others 
doing the tasks or if we are always asking what we should do. The support is important, but 
autonomy is essential for our growth. 
During internship I helped on submissions, but I had not the opportunity to make 
submissions alone and I did not had opportunity to make any reporting of adverse events or 
serious adverse events. The main reason was because of the short time performing functions 
as CRC. 
In Blueclinical Back Office, being responsible for contract revision, gave me opportunity to 
work with different sponsors and obliged me to work with different people and documents, 
so I had to adapt myself. Also, improvement of communication skills became visible. 
Communication became clearer, shorter, and objective and I started to justify and argue my 
point of view during contract negotiating. At first, I had some constrains with CRO and 
pharmaceutical companies. Now, I feel most of these constraints with industry were totally 
overcome as it is in the best interest of all parties, because the quicker the submission is, the 
quicker the study and recruitment can start. 
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Writing SOPs was a challenging activity as I had never written one. This task was performed 
at the end of my internship and I believe I performed it in the right time. I already had some 
experience in the tasks performed, and I did not felt it was difficult.   I believe the best advice 
I had before writing it was “try to detail your activities the way you think the process should 
ideally always occur”. That’s what I did, and I believe I was successful. 
Major personal competences developed were: 
- Autonomy; 
- Responsibility; 
- Time Management; 
- Conflict resolution; 
- Ability to set priorities, planning and coordination of multi-tasking skill; 
- Team work among different healthcare professionals; 
- Problem solving; 
- Priority management; 
- Assertiveness. 
Major technical competences developed were: 
- Deep understanding of legislation and guidelines applicable for clinical research; 
- Medical and scientific terminology; 
- Knowledge of the various stages of a study in a clinical trial site; 
- Protocols comprehension; 
- Financial agreements review; 
- Development tools for payment tracking; 
- Understanding quality manual system. 
I am grateful for the responsibilities and opportunities that Blueclinical provided me during 
internship. 
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5 CONCLUSION 
 
This training model proved to be efficacious to me, as it helped me to consolidate all I had 
learned in the first year of the master. The background obtained in the first years was 
determinant to successfully conduct the assigned tasks. 
This curricular training contributed to my experience and for the development of my skills. 
Besides using and consolidating academic background from the master it gave me a good 
insight of marketplace, providing me a good vision of the Pharmaceutical Industry and 
clinical research. During this period I had opportunity to perform different tasks, and I felt 
several difficulties as already explained but I think I could overcome them. This internship, 
helped me to learn with acquired experience, in a daily basis. In all difficulties and obstacles 
I encountered during this stage, I also I found an opportunity for growth and improvement, 
taking advantage of daily experiences to do better in future. 
 I believe the objectives proposed for this 9 month internship were successfully 
accomplished.
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